Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis.

Jensen, I.S., Wu, E., Fan, W. et al. (5 more authors) (2016) Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis. Journal of managed care & specialty pharmacy, 22 (6). pp. 752-764. ISSN 2376-0540

Abstract

Metadata

Authors/Creators:
  • Jensen, I.S.
  • Wu, E.
  • Fan, W.
  • Lodise, T.P.
  • Nicolau, D.P.
  • Dufour, S.
  • Cyr, P.L.
  • Sulham, K.A.
Copyright, Publisher and Additional Information: © 2016 Academy of Managed Care Pharmacy
Dates:
  • Published: June 2016
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Depositing User: Symplectic Sheffield
Date Deposited: 31 Aug 2016 10:27
Last Modified: 31 Aug 2016 10:27
Published Version: http://dx.doi.org/10.18553/jmcp.2016.22.6.752
Status: Published
Publisher: Academy of Managed Care Pharmacy
Refereed: Yes
Identification Number: https://doi.org/10.18553/jmcp.2016.22.6.752
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics